OneThree Biotech announced a collaboration with Sun Pharma Advanced Research Company Ltd. to enhance understanding of the biological mechanisms driving a key oncologic disease pathway. The collaboration will entail application of OneThree Biotech's Artificial Intelligence platform to fully characterize an enzyme pathway that metabolizes specific salts or esters involved in oncogenesis. The two companies thus aim to facilitate the discovery and development of innovative anticancer compounds and combination therapies to advance precision oncology. As part of the collaboration, OneThree Biotech will use its proprietary database, which integrates over 40 types for data from 100+ different sources – in combination with its AI platform to identify key drivers in the oncologic pathway the two companies are investigating, identify optimal cancer subtypes based on predicted vulnerabilities, and identify new ways to treat these subtypes. The analysis is expected to generate insights that can be used to identify patient populations that are likely to be sensitive to each type of inhibition, as well as potential single and combination therapies for SPARC to pursue into further preclinical and clinical development.